Sección de Evaluación de Resultados

Este Grupo tiene como objetivos recoger información sobre seguridad de las intervenciones en el mundo real; conocer cuál es el impacto de la inversión sanitaria en resultados de salud; aportar componentes, soluciones y herramientas para superar las barreras que impiden la implementación del real world data; recomponer la idea de innovación mediante el uso de real world data procedente de estudios postautorización y de la recogida sistemática y valorar nuevas formas de financiación de las intervenciones sanitarias. p>

 
Comité Ejecutivo

  • Dra. Nuria Ribelles Entrena. Hospitales Universitarios Regional y Virgen de la Victoria. (Málaga).  Coordinadora
  • Dra. Isabel Álvarez López. Hospital Donostia-Donostia Ospitalea (Donostia-San Sebastián). Vocal
  • Dr. Alberto Carmona Bayonas. . Hospital Universitario Morales Meseguer (Murcia). Vocal
  • Dra. Ana Belén Custodio Carretero. Hospital Universitario La Paz (Madrid) Vocal
  • Dr. Javier Gallego Plazas. Hospital General Universitario de Elche (Alicante). Vocal Representante de JD
  • Dr. Borja González Gómez. Hospital Universitario Lucus Augusti (Lugo) Vocal
  • Dr. José Manuel Jerez Aragonés. Universidad de Málaga (Málaga). Vocal 
  • Dra. Paula Jiménez Fonseca. HUCA (Hospital Universitario Central de Asturias). Vocal 
  • Dr. Martín Lázaro Quintela. Hospital Alvaro Cunqueiro-Complejo Hospitalario Universitario de Vigo. Vocal
  • Dra. Noelia Martínez Jañez Hospital Universitario Ramón y Cajal (Madrid).  Vocal
  • Dra. Vilma Pacheco Barcia. Hospital Universitario de Torrejón (Madrid). Vocal

Artículos de interés
  1. Comparison of Population-Based Observational Studies With Randomized Trials in Oncology
  2. Effectiveness in the Absence of Efficacy: Cautionary Tales From Real-World Evidence
  3. Electronic health records and patient registries in medical oncology departments in Spain
  
Artículos de interés - Registro de Cáncer Esofagogástrico AGAMENON
  1. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry
  2. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer
  3. Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab
  4. Anthracycline-based triplets do not improve the efficacyof platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world datafrom the AGAMEMON National Cancer Registry
  5. Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry
  6. Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis
  7. Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry
  8. Multistate Models: Accurate and Dynamic Methods to Improve Predictions of Thrombotic Risk in Patients with Cancer
  9. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
  10. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry
  11. External validity ofidocetaxel triplet trials iniadvanced gastric cancer:  are there patients who still beneft?
  12. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
  13. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the  AGAMENON-SEOM registry
  14. Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
  15. Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries
  16. Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
  17. Does HER2 status inluence in the beneit of ramucirumab and paclitaxel as second line treatment of advanced gastro‑esophageal adenocarcinoma? Data from the AGAMENON‑SEOM registry
  18. The AGAMENON-SEOM model for  prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
  19. Eicacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON‑SEOM registry
  20. Is there a preferred platinum and luoropyrimidine regimen for advanced HER2‑negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry

CONTACTO

SEOM

LEGAL